A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)

A Clinical Study to Evaluate the Relative Bioavailability of Enlicitide Test Formulations Under Fed and Fasted Conditions and Compare to the Reference FMF Tablet in Healthy Adult Participants

The goal of this trial is to learn what happens to different formulations (types) of enlicitide in a healthy person's body over time. Researchers will compare the amount of enlicitide in a healthy person's body over time when different formulations are given on an empty stomach and after a high-fat meal.

Inclusion Criteria:

• Is in good health
• Has a body-mass index (BMI) between ≥18.0 and ≤32.0 kg/m^2

Exclusion Criteria:

• Has history of gastrointestinal (GI) disease which might affect food and drug absorption or has had gastric bypass or similar surgery. Examples of GI disease include (but are not limited to) recurrent vomiting, inflammatory bowel disease, chronic intestinal disease accompanied by a disturbance in digestion and absorption, Roemheld's syndrome, and severe hernia
• Has a history of cancer (malignancy)
• Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
• Is lactose intolerant